The website gap that makes great science look unproven
Someone interested in your company looks you up before they ever reach out. An investor between meetings, a potential partner doing a first pass, a scientist deciding whether to email you. They land on your website, spend a few seconds, and form a verdict you never see. The science did not change in those seconds. The read of the science did.
That gap, between how good the work is and how credible it looks, is one of the most common and most fixable problems we see on biotech websites.
The meeting happens before the meeting
Buying behavior has moved upstream. Gartner finds that 75% of B2B buyers prefer a rep-free experience, doing their own research before they ever talk to you. By recent estimates, they spend roughly five hours researching for every hour with a vendor’s sales team.
So your website is not a brochure you point people to after the conversation. For most of the decision, it is the conversation. It is doing the talking when you are not in the room, and it is forming impressions that are hard to reverse later.
Why a weak site reads as weak science
The mechanism that makes this expensive is simple. In the few seconds someone spends on your site, they cannot actually evaluate the science. So they judge it by proxy, using the signals they can assess quickly: clarity, consistency, how current the site is, and the craft of the page.
When those signals are off, the brain quietly discounts the science sitting behind them. A visitor forms a view of a company’s credibility within seconds, well before they parse a single claim. Design and clarity end up standing in for the science itself.
In life science the stakes are higher, not lower. Get a design detail wrong, such as an incorrect illustration or a mechanism diagram that does not hold up, and the scientists in the room notice immediately. A small error in how you depict the work can cost more than having no visual at all.
The five gaps we see most
Across the credibility reviews we run, the same issues recur:
1. No answer in ten seconds. A visitor cannot tell what you do, who you are, and what stage you are at. If those three are not obvious fast, attention is already gone.
2. The site and the story have drifted apart. The deck says one thing, the homepage another. Misalignment does not read as nuance; it reads as disorganization.
3. Claims without proof. “Leading,” “novel,” “end-to-end,” with nothing specific underneath. Unbacked superlatives lower trust rather than raise it.
4. Stale signals. An old pipeline, dead news from two years ago, a copyright date that has lapsed. Each one whispers that the company may be stalling.
5. No named humans. No real team, no faces. In a business built on trust, anonymity reads as risk.
The tell: would it survive scrutiny?
A useful test is not “is it beautiful.” It is “does it hold up when an experienced investor or scientist pokes at it.” That is what we mean by built for scrutiny: every claim, visual, and number designed to withstand a hard second look, because that is exactly the look it will get.
What “credible” looks like
Credible does not mean expensive or flashy, and the most investable sites are often the plainest. But plain is not the same as careless. Credibility comes from three things working together.
The story. Your homepage should answer what you do, who you are, and what stage you are at within seconds, and every page after it should tell that same story without contradicting itself. The site should read the way you would want a sharp colleague to summarize you when you are not in the room. Most sites do not fail because they are ugly. They fail because the story is fuzzy or drifts from page to page.
The craft. Design and motion are not decoration when they carry meaning. Done well, they amplify the science rather than dress it up. When BioLattice’s site loads, blurred text resolves into focus, echoing a company working to restore vision. The Atlas hero encodes real mutation data instead of a generic spinning helix. That is the opposite of polish for its own sake: it is craft in service of the message, and a scientist clocks the difference instantly. A specific message expressed through strong craft beats both an empty animation and a plain page.
The technical integrity. The site is current and maintained: live pipeline, recent news, working links, fast load, accessible, and solid on mobile. Stale or broken signals read as a company that has stopped paying attention, which is the last thing an investor wants to fund.
Get those three right and the site stops undercutting the science. That is the bar we unpack in what makes a biotech website investor-ready, the companion to this piece, and it is what stood behind the Covant brand and website work that preceded a $481M partnership.
Closing the gap is a credibility decision, not a design project
The website is where credibility is won or lost before the science gets a hearing. That is why the fix is not a coat of paint. It is strategic. The story comes first, then the design and build express it, in one throughline rather than a series of handoffs.
The same logic runs through why an unclear story costs you the raise and how buyers decide whether you are a tool or a platform. The surface is where the substance gets judged.
Curious how your own site is landing with investors and buyers? Apply for Signal for an honest, specific read.